Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,791.60
(
0.00%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
104.71
(
0.50%
)
Bitcoin
80,974.99
(
-0.10%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: masterlongevity post# 156656

Tuesday, 10/29/2013 4:21:01 PM

Tuesday, October 29, 2013 4:21:01 PM

Post# of 257566
AMGN starts two phase-3 trials of Humira FoB called APB 501:

RA; 500 patients; expected completion Apr 2015:
http://clinicaltrials.gov/ct2/show/NCT01970488

Psoriasis; 340 patients; expected completion Aug 2015:
http://clinicaltrials.gov/ct2/show/NCT01970488

ACT is a partner on this FoB program; AMGN is responsible for manufacturing and clinical trials, while ACT pays a portion of the development costs (#msg-70097496).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today